Pretreatment integrase strand transfer inhibitor resistance in North Carolina from 2010-2016

AIDS

Volumn 31, Issue 16, 2017, Pages 2235-2244

  Menza, Timothy W ^a   Billock, Rachael ^b   Samoff, Erika ^c   Eron, Joseph J ^a   Dennis, Ann M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c North Carolina Department of Public Health   (United States)

Author keywords

cluster analysis; HIV; integrase strand transfer inhibitors; phylogenetic analysis; transmitted drug resistance

Indexed keywords

ANTIVIRUS AGENT; INTEGRASE INHIBITOR; INTEGRASE STRAND TRANSFER INHIBITOR; PROTEINASE; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLUSTER ANALYSIS; COHORT ANALYSIS; FEMALE; GENE MUTATION; GENOTYPE; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MIDDLE AGED; MOLECULAR GENETICS; MOLECULAR PHYLOGENY; NONHUMAN; NORTH CAROLINA; NUCLEOTIDE SEQUENCE; PATIENT REFERRAL; PERSONAL EXPERIENCE; PHYLOGENETIC TREE; PRIORITY JOURNAL; PUBLIC HEALTH; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; VIRUS LOAD; VIRUS TRANSMISSION; YOUNG ADULT; CLASSIFICATION; DISEASE TRANSMISSION; DRUG EFFECT; GENETICS; GENOTYPING TECHNIQUE; ISOLATION AND PURIFICATION; PHYLOGENY; PREVALENCE; TRANSMISSION; VIROLOGY;

ADULT; DISEASE TRANSMISSION, INFECTIOUS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HIV; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; NORTH CAROLINA; PHYLOGENY; PREVALENCE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85030752601     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001611     Document Type: Article

References (40)

1. HIV/AIDS Treatment Guidelines [Internet]. AIDSinfo. Available from: Https://aidsinfo.nih.gov/. [Accessed 10 August 2016]
2. Hurt CB. Transmitted resistance to HIV integrase strandtransfer inhibitors: Right on schedule. Antivir Ther 2011; 16: 137-140.
3. Yang WL, Kouyos R, Scherrer AU, Böni J, Shah C, Yerly S, et al., Swiss HIV Cohort Study. Assessing the paradox between transmitted and acquired HIV type 1 drug resistance mutations in the Swiss HIV Cohort Study from 1998 to 2012. J Infect Dis 2015; 212:28-38.
4. Boyd SD, Maldarelli F, Sereti I, Ouedraogo GL, Rehm CA, Boltz V, et al. Transmitted raltegravir resistance in an HIV-1 CRFAG-infected patient. Antivir Ther 2011; 16:257-261.
5. Volpe JM, Ward DJ, Napolitano L, Phung P, Toma J, Solberg O, et al. Five antiretroviral drug class-resistant HIV-1 in a treatment-näve patient successfully suppressed with optimized antiretroviral drug selection. J Int Assoc Provid AIDS Care 2015; 14:398-401.
6. Cossarini F, Boeri E, Canducci F, Salpietro S, Bigoloni A, Galli L, et al. integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-1 infection. J Acquir Immune Defic Syndr 2011; 56:e51-e54.
7. Frange P, Assoumou L, Descamps D, Chéret A, Goujard C, Tran L, et al., French ANRS CO 6 PRIMO Cohort, the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups; French ANRS CO 6 PRIMO Cohort the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups. HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: Impact on susceptibility to first-line strategies. J Antimicrob Chemother 2015; 70:2084-2089.
8. Scherrer AU, Yang WL, Kouyos RD, Bö ni J, Yerly S, Klimkait T, et al., Swiss HIV Cohort Study. Successful prevention of transmission of integrase resistance in the Swiss HIV Cohort Study. J Infect Dis 2016; 214:399-402.
9. Tostevin A, White E, Dunn D, Croxford S, Delpech V, Williams I, et al., UK HIV Drug Resistance Database. Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom. HIV Med 2017; 18:204-213.
10. Zoufaly A, Kraft C, Schmidbauer C, Puchhammer-Stoeckl E. Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013. Infection 2017; 45:165-170.
11. Jahanbakhsh F, Hattori J, Matsuda M, Ibe S, Monavari SH, Memarnejadian A, et al. Prevalence of transmitted HIV drug resistance in Iran between 2010 and 2011. PloS One 2013; 8:e61864.
12. Stekler JD, McKernan J, Milne R, Tapia KA, Mykhalchenko K, Holte S, et al. Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013. Antivir Ther 2015; 20:77-80.
13. Drug-Resistance Testing Adult and Adolescent ARV Guidelines [Internet]. AIDSinfo. Available from: Https://aidsinfo.nih.gov/. [Accessed 14 July 2017]
14. Hurt CB, Sebastian J, Hicks CB, Eron JJ. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis 2014; 58: 423-431.
15. Davy T, Napravnik S, Zakharova O, Eron JJ. Increased persistence of initial ART with INSTI-containing regimens. Conference on Retroviruses and Opportunistic Infections, Seattle, WA 2017.
16. Lepik KJ, Harrigan PR, Yip B, Wang L, Robbins MA, Zhang WW, et al. Emergent drug resistance with integrase strand transfer inhibitor-based regimens. AIDS 2017; 31: 1425-1434.
17. Bradley H, Hall HI, Wolitski RJ, Van Handel MM, Stone AE, LaFlam M, et al. Vital signs: HIV diagnosis, care, and treatment among persons living with HIV: United States, 2011. MMWR Morb Mortal Wkly Rep 2014; 63:1113-1117.
18. Dailey A F. HIV Care Outcomes Among Blacks with Diagnosed HIV: United States, 2014. MMWR Morb Mortal Wkly Rep [Internet] 2017 66. Available from: Http://www.cdc.gov/mmwr/volumes/66/wr/mm6604a2.htm/. [Accessed 17 February 2017]
19. Wensing AM, Calvez V, Günthard HF, Johnson VA, Paredes R, Pillay D, et al. 2015 update of the drug resistance mutations in HIV-1. Top Antivir Med 2015; 23:132-141.
20. Stanford University HIV Drug Resistance Database [Internet]. Available from: Https://hivdb.stanford.edu/hivdb/by-sequences/. [Accessed 21 February 2017]
21. Struck D, Lawyer G, Ternes AM, Schmit JC, Bercoff DP.comET: Adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res 2014; 42: E144.
22. Wertheim JO, Leigh Brown AJ, Hepler NL, Mehta SR, Richman DD, Smith DM, Kosakovsky Pond SL. The global transmission network of HIV-1. J Infect Dis 2014; 209:304-313.
23. Edgar RC. MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 2004; 32:1792-1797.
24. Tamura K, Nei M. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol Biol Evol 1993; 10: 512-526.
25. Price MN, Dehal PS, Arkin AP. FastTree 2: Approximately maximum-likelihood trees for large alignments. PLoS One 2010; 5:e9490.
26. Price MN, Dehal PS, Arkin AP. FastTree: Computing large minimum evolution trees with profiles instead of a distance matrix. Mol Biol Evol 2009; 26:1641-1650.
27. Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, et al. Impact of primary elvitegravir resistance-A ssociated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother 2013; 57:2654-2663.
28. Hardy I, Brenner B, Quashie P, Thomas R, Petropoulos C, Huang W, et al. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother 2015; 70:405-411.
29. Carganico A, Dupke S, Ehret R, Berg T, Baumgarten A, Obermeier M, Walter H. New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy. J Int AIDS Soc 2014; 17 (4 Suppl 3):19749.
30. Garcá-Lerma JG, MacInnes H, Bennett D, Weinstock H, Heneine W. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine. J Virol 2004; 78:7545-7552.
31. Garcá-Lerma JG. Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons. J Antimicrob Chemother 2005; 56:265-269.
32. Llácer Delicado T, Torrecilla E, Holgún Á . Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals. J Antimicrob Chemother 2016; 71:362-366.
33. Abram ME, Ram RR, Margot NA, Barnes TL, White KL, Callebaut C, Miller MD. Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome. PloS One 2017; 12: E0172206.
34. Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, MarcelinAG, Perno CF. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 2009; 11:17-29.
35. Mourad R, Chevennet F, Dunn DT, Fearnhill E, Delpech V, Asboe D, et al., UK HIV Drug Resistance Database & the Collaborative HIV, Anti-HIV Drug Resistance Network. A phylotype-based analysis highlights the role of drug-naive HIVpositive individuals in the transmission of antiretroviral resistance in the UK. AIDS 2015; 29:1917-1925.
36. Drescher SM, von Wyl V, Yang WL, Böni J, Yerly S, Shah C, et al., Swiss HIV Cohort Study. Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. Clin Infect Dis 2014; 58:285-294.
37. Kwakwa HA, Ghobrial MW. Female-to-female transmission of human immunodeficiency virus. Clin Infect Dis 2003; 36:e40-e41.
38. Mesplède T, Wainberg MA. Is resistance to dolutegravir possible when this drug is used in first-line therapy Viruses 2014; 6:3377-3385.
39. Oliveira M, Mesplède T, Quashie PK, Mösi D, Wainberg MA. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS 2014; 28:813-819.
40. Medicare Part D Claims for Tivicay (Dolutegravir) [Internet]. [cited 22 February 2017]. Available from: Https://projects. propublica.org/checkup/drugs/8149/. [Accessed 22 February 2017]